8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
May 7, 2026·SEC
Artivion, Inc.(AORT)Earnings, Financials & Key Ratios
AORT•NYSE
100.9× P/E·Price updated Jun 19, 2026
AboutArtivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.Show more
- Revenue$441M+13.6%
- EBITDA$49M-22.0%
- Net Income$10M+173.1%
- EPS (Diluted)0.21+165.6%
- Gross Margin61.28%-4.3%
- EBITDA Margin11.15%-31.3%
- Operating Margin6.06%-39.4%
- Net Margin2.21%+164.4%
- ROE2.7%+156.3%
AORT Key Insights
Artivion, Inc. (AORT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.8%
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Shares diluted 13.2% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AORT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AORT Price & Volume
Artivion, Inc. (AORT) stock price & volume — 10-year historical chart
Loading chart...
AORT Growth Metrics
Artivion, Inc. (AORT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.7%
5 Years11.75%
3 Years12.04%
TTM17.59%
Profit CAGR
10 Years9.33%
5 Years-
3 Years-
TTM154.63%
EPS CAGR
10 Years4.14%
5 Years-
3 Years-
TTM146.72%
Return on Capital
10 Years2.85%
5 Years2.33%
3 Years3.23%
Last Year3.55%
AORT Recent Earnings
Artivion, Inc. (AORT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.08+33.3%
$0.06
Rev
$116M+0.6%
$116M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.17+21.4%
$0.14
Rev
$116M-0.4%
$116M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.16+14.3%
$0.14
Rev
$113M-2.6%
$116M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.24+118.2%
$0.11
Rev
$113M+5.1%
$107M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.08vs $0.06+33.3% | $116Mvs $116M+0.6% |
| Q1 2026 | Feb 12, 2026 | $0.17vs $0.14+21.4% | $116Mvs $116M-0.4% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.14+14.3% | $113Mvs $116M-2.6% |
| Q3 2025 | Aug 7, 2025 | $0.24vs $0.11+118.2% | $113Mvs $107M+5.1% |
Based on last 12 quarters of dataView full earnings history →
AORT Peer Comparison
Artivion, Inc. (AORT) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NNOX | 109.19M | 1.67 | -1.84 | 13.91% | -452.82% | -35.55% | 0.04 | |
 TMDX | 2.72B | 78.79 | 16.18 | 37.13% | 27.04% | 41.92% | 0.99 | |
 MASI | 9.42B | 179.95 | -64.27 | -27.1% | 4.9% | 9.08% | 0.78 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 | |
 LMAT | 2.14B | 93.95 | 37.28 | 13.53% | 24.35% | 16.19% | 0.47 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% |
Compare AORT vs Peers
Artivion, Inc. (AORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AORT Income Statement
Artivion, Inc. (AORT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 189.7M | 262.84M | 276.22M | 253.23M | 298.84M | 313.79M | 354M | 388.54M | 441.33M | 458.69M |
Revenue Growth % | 5.17% | 38.55% | 5.09% | -8.32% | 18.01% | 5% | 12.82% | 9.75% | 13.59% | 17.59% |
Cost of Goods Sold | 61.06M | 89.86M | 93.21M | 85.44M | 101.32M | 111.27M | 124.83M | 139.76M | 170.88M | 169.99M |
COGS % of Revenue | 32.19% | 34.19% | 33.74% | 33.74% | 33.91% | 35.46% | 35.26% | 35.97% | 38.72% | - |
Gross Profit | 128.64M▲ 0% | 172.98M▲ 34.5% | 183.01M▲ 5.8% | 167.78M▼ 8.3% | 197.51M▲ 17.7% | 202.52M▲ 2.5% | 229.18M▲ 13.2% | 248.78M▲ 8.6% | 270.45M▲ 8.7% | 288.7M▲ 0% |
Gross Margin % | 67.81% | 65.81% | 66.26% | 66.26% | 66.09% | 64.54% | 64.74% | 64.03% | 61.28% | 62.94% |
Gross Profit Growth % | 8.19% | 34.47% | 5.8% | -8.32% | 17.72% | 2.54% | 13.16% | 8.55% | 8.71% | - |
Operating Expenses | 120.67M | 163.67M | 165.97M | 165.34M | 189.4M | 196.32M | 223.43M | 209.91M | 243.71M | 253.12M |
OpEx % of Revenue | 63.61% | 62.27% | 60.09% | 65.29% | 63.38% | 62.57% | 63.12% | 54.02% | 55.22% | - |
Selling, General & Admin | 101.21M | 140.57M | 143.01M | 141.14M | 169.77M | 157.44M | 208.98M | 192.38M | 212.72M | 220.91M |
SG&A % of Revenue | 53.35% | 53.48% | 51.77% | 55.73% | 56.81% | 50.17% | 59.03% | 49.51% | 48.2% | - |
Research & Development | 19.46M | 23.1M | 22.96M | 24.21M | 35.55M | 38.88M | 28.71M | 28.45M | 30.99M | 33.1M |
R&D % of Revenue | 10.26% | 8.79% | 8.31% | 9.56% | 11.89% | 12.39% | 8.11% | 7.32% | 7.02% | - |
Other Operating Expenses | 260K | -141K | 0 | 0 | -15.92M | 0 | -14.25M | -10.92M | 0 | -900K |
Operating Income | 7.97M▲ 0% | 9.31M▲ 16.8% | 17.04M▲ 83.0% | 2.44M▼ 85.7% | 8.12M▲ 232.5% | 6.2M▼ 23.6% | 5.74M▼ 7.4% | 38.87M▲ 577.0% | 26.75M▼ 31.2% | 35.59M▲ 0% |
Operating Margin % | 4.2% | 3.54% | 6.17% | 0.96% | 2.72% | 1.98% | 1.62% | 10.01% | 6.06% | 7.76% |
Operating Income Growth % | -63.47% | 16.84% | 83.01% | -85.68% | 232.53% | -23.6% | -7.4% | 577.01% | -31.2% | - |
EBITDA | 17.7M | 27.41M | 35.36M | 23.15M | 32.09M | 28.64M | 28.82M | 63.08M | 49.2M | 58.94M |
EBITDA Margin % | 9.33% | 10.43% | 12.8% | 9.14% | 10.74% | 9.13% | 8.14% | 16.23% | 11.15% | 12.85% |
EBITDA Growth % | -41.39% | 54.82% | 29.01% | -34.52% | 38.62% | -10.75% | 0.61% | 118.89% | -22% | 49.4% |
D&A (Non-Cash Add-back) | 9.73M | 18.09M | 18.32M | 20.71M | 23.98M | 22.44M | 23.08M | 24.2M | 22.46M | 23.35M |
EBIT | 8.44M | 12.11M | 16.53M | -476K | 2.06M | 3.24M | 3.71M | 26.76M | 26.75M | 38.59M |
Net Interest Income | -4.67M | -15.56M | -14.15M | -16.48M | -16.81M | -18.08M | -24.22M | -32.81M | -25.82M | -23.46M |
Interest Income | 212K | 226K | 738K | 217K | 79K | 147K | 1.08M | 1.47M | 763K | 824K |
Interest Expense | 4.88M | 15.79M | 14.89M | 16.7M | 16.89M | 18.22M | 25.3M | 34.28M | 26.58M | 24.29M |
Other Income/Expense | -4.41M | -15.7M | -15.4M | -19.61M | -22.94M | -21.18M | -27.33M | -46.39M | -11.96M | -18.17M |
Pretax Income | 3.56M▲ 0% | -6.39M▼ 279.5% | 1.64M▲ 125.7% | -17.17M▼ 1144.6% | -14.83M▲ 13.7% | -14.98M▼ 1.1% | -21.59M▼ 44.1% | -7.51M▲ 65.2% | 14.78M▲ 296.7% | 17.41M▲ 0% |
Pretax Margin % | 1.88% | -2.43% | 0.6% | -6.78% | -4.96% | -4.78% | -6.1% | -1.93% | 3.35% | 3.8% |
Income Tax | -143K | -2.59M | -76K | -492K | 7K | 4.21M | 9.1M | 5.84M | 5.01M | 5.72M |
Effective Tax Rate % | -4.02% | 40.46% | -4.62% | 2.86% | -0.05% | -28.08% | -42.18% | -77.79% | 33.91% | 32.87% |
Net Income | 3.7M▲ 0% | -3.81M▼ 202.7% | 1.72M▲ 145.2% | -16.68M▼ 1069.9% | -14.83M▲ 11.1% | -19.19M▼ 29.4% | -30.69M▼ 59.9% | -13.36M▲ 56.5% | 9.77M▲ 173.1% | 11.69M▲ 0% |
Net Margin % | 1.95% | -1.45% | 0.62% | -6.59% | -4.96% | -6.12% | -8.67% | -3.44% | 2.21% | 2.55% |
Net Income Growth % | -65.63% | -202.73% | 145.2% | -1069.88% | 11.08% | -29.38% | -59.91% | 56.47% | 173.12% | 154.63% |
Net Income (Continuing) | 3.7M | -2.84M | 1.72M | -16.68M | -14.83M | -19.19M | -30.69M | -13.36M | 9.77M | 11.69M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.11▲ 0% | -0.10▼ 190.9% | 0.05▲ 145.1% | -0.44▼ 1075.6% | -0.38▲ 13.6% | -0.48▼ 26.3% | -0.75▼ 56.3% | -0.32▲ 57.3% | 0.21▲ 165.6% | 0.24▲ 0% |
EPS Growth % | -65.63% | -190.91% | 145.1% | -1075.61% | 13.64% | -26.32% | -56.25% | 57.33% | 165.63% | 146.72% |
EPS (Basic) | 0.11 | -0.11 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.22 | - |
Diluted Shares Outstanding | 34.16M | 36.41M | 37.86M | 37.86M | 38.98M | 40.03M | 40.74M | 41.68M | 47.16M | 49.73M |
Basic Shares Outstanding | 33.01M | 35.16M | 37.12M | 37.86M | 38.98M | 40.03M | 40.74M | 41.68M | 45.34M | 48.07M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AORT Balance Sheet
Artivion, Inc. (AORT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 179.28M | 179.17M | 187.39M | 234.59M | 247.7M | 247.33M | 280.67M | 290.08M | 303.55M | 304.1M |
Cash & Short-Term Investments | 40.75M | 41.49M | 33.77M | 61.41M | 55.01M | 39.35M | 58.94M | 53.46M | 64.91M | 55.76M |
Cash Only | 40.75M | 41.49M | 33.77M | 61.41M | 55.01M | 39.35M | 58.94M | 53.46M | 64.91M | 55.76M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 51.44M | 51.43M | 55.86M | 48.75M | 58.1M | 69.58M | 74.14M | 85.89M | 103.68M | 105.62M |
Days Sales Outstanding | 98.98 | 71.42 | 73.81 | 70.27 | 70.97 | 80.94 | 76.44 | 80.69 | 85.75 | 81.15 |
Inventory | 46.68M | 45.48M | 53.07M | 73.04M | 76.97M | 74.48M | 81.98M | 79.77M | 92.43M | 98M |
Days Inventory Outstanding | 279.06 | 184.73 | 207.82 | 312.01 | 277.28 | 244.32 | 239.7 | 208.32 | 197.43 | 147.76 |
Other Current Assets | 36.45M | 33.92M | 33.08M | 37.09M | 42.86M | 46.37M | 49.8M | 70.96M | 42.54M | 44.73M |
Total Non-Current Assets | 412.39M | 391.92M | 418.26M | 554.82M | 545.36M | 515.46M | 511.73M | 499.02M | 581.25M | 579.05M |
Property, Plant & Equipment | 33.58M | 31.03M | 54.14M | 51.65M | 83.23M | 80.53M | 82.18M | 76.13M | 99.69M | 102.3M |
Fixed Asset Turnover | 5.65x | 8.47x | 5.10x | 4.90x | 3.59x | 3.90x | 4.31x | 5.10x | 4.43x | 7.01x |
Goodwill | 188.31M | 188.78M | 186.7M | 260.06M | 250M | 243.63M | 247.34M | 240.96M | 254.09M | 251.66M |
Intangible Assets | 179.43M | 160.08M | 157.73M | 227.06M | 201.5M | 182.65M | 172.23M | 156.38M | 156.5M | 154.89M |
Long-Term Investments | 1.98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 7.49M | 7.92M | 14.21M | 14.6M | 8.27M | 7.34M | 8.89M | 24.48M | 69.77M | 69.07M |
Total Assets | 591.67M▲ 0% | 571.09M▼ 3.5% | 605.65M▲ 6.1% | 789.4M▲ 30.3% | 793.05M▲ 0.5% | 762.8M▼ 3.8% | 792.4M▲ 3.9% | 789.1M▼ 0.4% | 884.8M▲ 12.1% | 883.16M▲ 0% |
Asset Turnover | 0.32x | 0.46x | 0.46x | 0.32x | 0.38x | 0.41x | 0.45x | 0.49x | 0.50x | 0.53x |
Asset Growth % | 87.15% | -3.48% | 6.05% | 30.34% | 0.46% | -3.81% | 3.88% | -0.42% | 12.13% | 36.73% |
Total Current Liabilities | 42.94M | 34.52M | 45.2M | 60.47M | 44.95M | 49.67M | 57.86M | 66.82M | 101.56M | 92.7M |
Accounts Payable | 9.77M | 7.55M | 9.8M | 9.62M | 10.39M | 12M | 13.32M | 17.97M | 16.04M | 18.34M |
Days Payables Outstanding | 58.38 | 30.66 | 38.36 | 41.11 | 37.45 | 39.38 | 38.94 | 46.93 | 34.27 | 37.74 |
Short-Term Debt | 1.3M | 1.89M | 1.16M | 1.2M | 1.63M | 1.61M | 1.45M | 195K | 5.38M | 5.53M |
Deferred Revenue (Current) | 29.45M | 2.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12.06M | 13.86M | 14.07M | 29.37M | 700K | 1.31M | 21.11M | 583K | 50.17M | 47.85M |
Current Ratio | 4.18x | 5.19x | 4.15x | 3.88x | 5.51x | 4.98x | 4.85x | 4.34x | 2.99x | 3.28x |
Quick Ratio | 3.09x | 3.87x | 2.97x | 2.67x | 3.80x | 3.48x | 3.43x | 3.15x | 2.08x | 2.22x |
Cash Conversion Cycle | 319.66 | 225.5 | 243.28 | 341.17 | 310.8 | 285.88 | 277.2 | 242.08 | 248.91 | 191.18 |
Total Non-Current Liabilities | 269.69M | 261.5M | 274.76M | 400.22M | 447.37M | 428.79M | 452.75M | 446.08M | 335.01M | 339.99M |
Long-Term Debt | 218.24M | 215.72M | 214.57M | 290.47M | 307.49M | 306.5M | 305.53M | 314.15M | 249.54M | 215.35M |
Capital Lease Obligations | 6.86M | 5.94M | 23.33M | 19.33M | 49.24M | 44.9M | 47.38M | 42.82M | 37.13M | 158.19M |
Deferred Tax Liabilities | 30.43M | 27.27M | 25.84M | 34.71M | 28.8M | 24.5M | 21.85M | 20.18M | 24.31M | 97.33M |
Other Non-Current Liabilities | 14.17M | 12.58M | 11.02M | 55.71M | 61.84M | 52.9M | 77.99M | 68.92M | 24.03M | 59.73M |
Total Liabilities | 312.63M | 296.02M | 319.96M | 460.69M | 492.32M | 478.47M | 510.62M | 512.9M | 436.56M | 432.69M |
Total Debt | 226.39M | 223.55M | 245.15M | 317.37M | 362.04M | 356.83M | 358.34M | 362.26M | 292.04M | 258.16M |
Net Debt | 185.63M | 182.06M | 211.39M | 255.96M | 307.03M | 317.48M | 299.4M | 308.8M | 227.13M | 202.39M |
Debt / Equity | 0.81x | 0.81x | 0.86x | 0.97x | 1.20x | 1.25x | 1.27x | 1.31x | 0.65x | 0.57x |
Debt / EBITDA | 12.79x | 8.16x | 6.93x | 13.71x | 11.28x | 12.46x | 12.43x | 5.74x | 5.94x | 4.38x |
Net Debt / EBITDA | 10.49x | 6.64x | 5.98x | 11.06x | 9.57x | 11.08x | 10.39x | 4.90x | 4.62x | 3.43x |
Interest Coverage | 1.73x | 0.77x | 1.11x | -0.03x | 0.12x | 0.18x | 0.15x | 0.78x | 1.01x | 1.59x |
Total Equity | 279.04M▲ 0% | 275.07M▼ 1.4% | 285.7M▲ 3.9% | 328.71M▲ 15.1% | 300.73M▼ 8.5% | 284.33M▼ 5.5% | 281.78M▼ 0.9% | 276.2M▼ 2.0% | 448.23M▲ 62.3% | 450.47M▲ 0% |
Equity Growth % | 33.52% | -1.42% | 3.86% | 15.06% | -8.51% | -5.45% | -0.9% | -1.98% | 62.29% | 201.64% |
Book Value per Share | 8.17 | 7.55 | 7.55 | 8.68 | 7.71 | 7.10 | 6.92 | 6.63 | 9.50 | 9.06 |
Total Shareholders' Equity | 279.04M | 275.07M | 285.7M | 328.71M | 300.73M | 284.33M | 281.78M | 276.2M | 448.23M | 450.47M |
Common Stock | 376K | 385K | 390K | 404K | 414K | 418K | 426K | 434K | 493K | 500K |
Retained Earnings | 37.61M | 34.98M | 36.7M | 20.02M | 1.98M | -17.22M | -47.91M | -61.27M | -51.5M | -50.08M |
Treasury Stock | -12.72M | -14.59M | -14.59M | -14.65M | -14.65M | -14.65M | -14.65M | -14.65M | -14.65M | -14.65M |
Accumulated OCI | 1.86M | -6.07M | -8.59M | 6.74M | -9.89M | -21.61M | -12.01M | -24.93M | -2.72M | -11.56M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AORT Cash Flow Statement
Artivion, Inc. (AORT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 10.8M | 9.88M | 15.83M | 12.37M | -2.58M | -5.15M | 18.82M | 22.24M | 38.13M | 56.24M |
Operating CF Margin % | 5.69% | 3.76% | 5.73% | 4.88% | -0.86% | -1.64% | 5.32% | 5.72% | 8.64% | - |
Operating CF Growth % | -45.22% | -8.53% | 60.18% | -21.85% | -120.9% | -99.34% | 465.32% | 18.12% | 71.48% | 423.47% |
Net Income | 3.7M | -2.84M | 1.72M | -3.46M | -14.83M | -19.19M | -30.69M | -13.36M | 9.77M | 11.69M |
Depreciation & Amortization | 9.74M | 18.09M | 18.32M | 27.86M | 23.98M | 22.44M | 23.08M | 24.2M | 22.46M | 23.35M |
Stock-Based Compensation | 6.92M | 6.33M | 8.8M | 6.91M | 10.71M | 12.34M | 14.42M | 14.24M | 24.39M | 0 |
Deferred Taxes | -1.48M | -4.49M | -2.31M | 4.28M | -4.47M | -1.72M | -1.39M | -1.51M | 37K | -487K |
Other Non-Cash Items | 2.79M | 2.8M | 8.68M | 3.47M | 15.26M | 6.91M | 29.59M | 15.9M | 3.64M | 36.22M |
Working Capital Changes | -10.87M | -10.01M | -19.38M | -26.7M | -33.23M | -25.94M | -16.19M | -17.24M | -22.16M | -14.53M |
Change in Receivables | -7.26M | -5.91M | -3.38M | 9.94M | -11.56M | -13.34M | -4.05M | -15.39M | -7.27M | -2.11M |
Change in Inventory | -9.37M | 2.38M | -8.13M | -24.76M | -18.38M | -8.4M | -14.36M | -6.14M | -15.28M | -19.2M |
Change in Payables | 8.73M | -8.87M | 251K | -9.16M | -1.89M | -1.96M | 1.68M | 9.5M | 2.18M | 9.53M |
Cash from Investing | -170.99M | -6.71M | -23.94M | -73.13M | 5.66M | -10.71M | -502K | -28.19M | -42.04M | -48.91M |
Capital Expenditures | -7.04M | -5.79M | -8.07M | -7.33M | -13.09M | -10.71M | -7.43M | -11.19M | -39.04M | -43.41M |
CapEx % of Revenue | 3.71% | 2.2% | 2.92% | 2.89% | 4.38% | 3.41% | 2.1% | 2.88% | 8.85% | 9.46% |
Acquisitions | -163.92M | 0 | 0 | -59.12M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -86K | -929K | -15.87M | -6.68M | -249K | 0 | 6.93M | -17M | -3M | -5.5M |
Cash from Financing | 143.25M | -2.56M | -1.49M | 93.61M | -12.22M | -1.64M | 865K | 2.2M | 13.03M | 9.56M |
Debt Issued (Net) | 152.79M | -2.79M | -2.78M | 94.65M | -3.08M | -2.75M | -2.77M | -358K | -2.46M | 146K |
Equity Issued (Net) | -1.61M | -2.1M | -2.74M | -2M | -1.91M | -1.79M | -559K | 5.73M | 13.07M | 10.14M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -1.61M | -2.1M | -2.74M | -2M | -1.91M | -1.79M | -559K | 0 | 0 | 0 |
Other Financing | -7.93M | 2.33M | 4.03M | 949K | -7.22M | 2.91M | 4.2M | -3.17M | 2.42M | -731K |
Net Change in Cash | -16.66M▲ 0% | 1.48M▲ 108.9% | -7.94M▼ 635.5% | 27.66M▲ 448.3% | -6.95M▼ 125.1% | -15.66M▼ 125.4% | 19.59M▲ 225.1% | -5.48M▼ 128.0% | 11.45M▲ 309.0% | 18.07M▲ 0% |
Free Cash Flow | 3.76M▲ 0% | 4.09M▲ 8.9% | 7.75M▲ 89.4% | 5.04M▼ 35.0% | -15.68M▼ 411.0% | -15.87M▼ 1.2% | 11.39M▲ 171.8% | 11.05M▼ 3.0% | -911K▼ 108.2% | 12.83M▲ 0% |
FCF Margin % | 1.98% | 1.56% | 2.81% | 1.99% | -5.25% | -5.06% | 3.22% | 2.84% | -0.21% | 2.8% |
FCF Growth % | -69.4% | 8.85% | 89.38% | -35% | -410.97% | -1.22% | 171.81% | -3.05% | -108.25% | 3022.78% |
FCF per Share | 0.11 | 0.11 | 0.20 | 0.13 | -0.40 | -0.40 | 0.28 | 0.27 | -0.02 | 0.26 |
FCF Conversion (FCF/Net Income) | 2.92x | -2.60x | 9.20x | -0.74x | 0.17x | 0.27x | -0.61x | -1.66x | 3.90x | 1.10x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AORT Key Ratios
Artivion, Inc. (AORT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 1.52% | -1.37% | 0.61% | -5.43% | -4.71% | -6.56% | -10.84% | -4.79% | 2.7% | 2.66% |
Return on Invested Capital (ROIC) | 1.74% | 1.52% | 2.68% | 0.34% | 1.02% | 0.77% | 0.73% | 5% | 3.18% | 4.07% |
Gross Margin | 67.81% | 65.81% | 66.26% | 66.26% | 66.09% | 64.54% | 64.74% | 64.03% | 61.28% | 62.94% |
Net Margin | 1.95% | -1.45% | 0.62% | -6.59% | -4.96% | -6.12% | -8.67% | -3.44% | 2.21% | 2.55% |
Debt / Equity | 0.81x | 0.81x | 0.86x | 0.97x | 1.20x | 1.25x | 1.27x | 1.31x | 0.65x | 0.57x |
Interest Coverage | 1.73x | 0.77x | 1.11x | -0.03x | 0.12x | 0.18x | 0.15x | 0.78x | 1.01x | 1.59x |
FCF Conversion | 2.92x | -2.60x | 9.20x | -0.74x | 0.17x | 0.27x | -0.61x | -1.66x | 3.90x | 1.10x |
Revenue Growth | 5.17% | 38.55% | 5.09% | -8.32% | 18.01% | 5% | 12.82% | 9.75% | 13.59% | 17.59% |
Related:AORT Dividend History·AORT Revenue History·AORT Price History·AORT P/E History·AORT Financial Ratios·AORT Institutional Holders
AORT SEC Filings & Documents
Artivion, Inc. (AORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
AORT Frequently Asked Questions
Artivion, Inc. (AORT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Artivion, Inc. (AORT) reported $458.7M in revenue for fiscal year 2025. This represents a 1140% increase from $37.0M in 1996.
Artivion, Inc. (AORT) grew revenue by 13.6% over the past year. This is steady growth.
Yes, Artivion, Inc. (AORT) is profitable, generating $11.7M in net income for fiscal year 2025 (2.2% net margin).
Dividend & Returns
Artivion, Inc. (AORT) has a return on equity (ROE) of 2.7%. This is below average, suggesting room for improvement.
Artivion, Inc. (AORT) generated $12.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.